Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus

Journal of Gastroenterology and Hepatology (Australia)

Volumn 31, Issue 7, 2016, Pages 1323-1329

  Chuang, Wan Long ^a   Chien, Rong Nan ^b   Peng, Cheng Yuan ^c   Chang, Ting Tsung ^d   Lo, Gin Ho ^e   Sheen, I Shyan ^f   Wang, Horng Yuan ^g   Chen, Jyh Jou ^h   Yang, Jenny C ⁱ   Knox, Steven J ⁱ   Gao, Bing ⁱ   Garrison, Kimberly L ⁱ   Mo, Hongmei ⁱ   Pang, Phillip S ⁱ   Hsu, Yu Chun ^j   Hu, Tsung Hui ^k   Chu, Chi Jen ^l   Kao, Jia Horng ^m  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^e E DA HOSPITAL   (Taiwan)

^f CHANG GUNG UNIVERSITY   (Taiwan)

^g MACKAY MEMORIAL HOSPITAL   (Taiwan)

^h CHI MEI MEDICAL CENTER   (Taiwan)

ⁱ GILEAD SCIENCES   (United States)

^j CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^k Chang Gung Medical Foundation   (Taiwan)

^l NATIONAL YANG MING UNIVERSITY   (Taiwan)

^m NATIONAL TAIWAN UNIVERSITY   (Taiwan)

more..

Author keywords

hepatitis C virus (HCV); infection; ledipasvir; sofosbuvir; Taiwan

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; LEDIPASVIR PLUS SOFOSBUVIR; BENZIMIDAZOLE DERIVATIVE; CARBAMIC ACID DERIVATIVE; DRUG COMBINATION; FLUORENE DERIVATIVE; FUSED HETEROCYCLIC RINGS; LEDIPASVIR; SOFOSBUVIR; SOFOSBUVIR-VELPATASVIR DRUG COMBINATION; TABLET;

ADENOMYOSIS; ADULT; AGED; ARTICLE; CANCER PATIENT; CHRONIC HEPATITIS C; COMPENSATED LIVER CIRRHOSIS; COUGHING; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIOSIS; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPHIL COUNT; OPEN STUDY; PERSONAL EXPERIENCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RHINOPHARYNGITIS; SIDE EFFECT; SMALL CELL LUNG CANCER; TAIWANESE; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; CLINICAL TRIAL; DRUG COMBINATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; TABLET; TAIWAN; TREATMENT OUTCOME; VIROLOGY;

ADULT; AGED; BENZIMIDAZOLES; CARBAMATES; DRUG COMBINATIONS; FEMALE; FLUORENES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HUMANS; MALE; MIDDLE AGED; SOFOSBUVIR; TABLETS; TAIWAN; TREATMENT OUTCOME;

EID: 84979523519     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13305     Document Type: Article

References (31)

1. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin. Microbiol. Infect. 2011; 17: 107–15.
2. Chen CH, Yang PM, Huang GT, Lee HS, Sung JL, Sheu JC. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J. Formos. Med. Assoc. 2007; 106: 148–55.
3. Kao JH. Hepatitis C virus infection in Taiwan: past, present and future. J. Formos. Med. Assoc. 2015. DOI: 10.1016/j.jfma.2015.06.012[epub ahead of print].
4. Lee MH, Yang HI, Lu SN et al. Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study. J. Clin. Oncol. 2010; 28: 4587–93.
5. Lee MH, Yang HI, Lu SN et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J. Infect. Dis. 2012; 206: 469–77.
6. Lee MH, Yang HI, Lu SN et al. Hepatitis C virus genotype 1b increases cumulative lifetime risk of hepatocellular carcinoma. Int. J. Cancer 2014; 135: 1119–26.
7. Yu ML, Chuang WL, Chen SC et al. Changing prevalence of hepatitis C virus genotypes: molecular epidemiology and clinical implications in the hepatitis C virus hyperendemic areas and a tertiary referral center in Taiwan. J. Med. Virol. 2001; 65: 58–65.
8. Omata M, Kanda T, Yu M-L et al. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol. Int. 2012; 6: 409–35.
9. Liu CH, Liu CJ, Lin CL et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naïve Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin. Infect. Dis. 2008; 47: 1260–9.
10. Liu CJ, Chuang WL, Lee CM et al. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 2009; 136: 496–504.e3.
11. Yu ML, Dai CY, Huang JF et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008; 47: 1884–93.
12. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–65.
13. Hadziyannis SJ, Sette H Jr, Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 2004; 140: 346–55.
14. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002; 347: 975–82.
15. Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J. Gastroenterol. Hepatol. 2009; 24: 336–45.
16. Hsu CS, Hsu SJ, Chen HC et al. Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. Proc. Natl. Acad. Sci. U. S. A. 2011; 108: 3719–24.
17. Chen JY, Lin CY, Wang CM et al. IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-α plus ribavirin therapy in Taiwanese chronic HCV infection. Genes Immun. 2011; 12: 300–9.
18. Hsu SJ, Hsu CS, Liu CH et al. HCV core gene polymorphisms correlate with liver fibrosis but not sustained virological response in patients with genotype 1 infection. Antivir. Ther. 2011; 16: 227–35.
19. Myers RP, Patel K, Pianko S, Poynard T, McHutchison JG. The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C. J. Viral Hepat. 2003; 10: 16–22.
20. Hu CC, Lin CL, Chang LC et al. Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study. B.M.C. Infect. Dis. 2015; 15: 156.
21. Gilead Sciences International Ltd. HARVONI (ledipasvir/sofosbuvir) Summary of Product Characteristics. Cambridge, UK: Gilead Sciences International Ltd, 2014.
22. Gilead Sciences, Inc. HARVONI (ledipasvir and sofosbuvir) Prescribing Information. Foster City, CA: Gilead Sciences, Inc., 2014.
23. Afdhal N, Zeuzem S, Kwo P et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N. Engl. J. Med. 2014; 370: 1889–98.
24. Kowdley KV, Gordon SC, Reddy KR et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N. Engl. J. Med. 2014; 370: 1879–88.
25. Afdhal N, Reddy KR, Nelson DR et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N. Engl. J. Med. 2014; 370: 1483–93.
26. Mizokami M, Yokosuka O, Takehara T et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naïve and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect. Dis. 2015; 15: 645–53.
27. Lim Y-S, Ahn SH, Lee K-S et al. A phase 3b study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus. J. Viral Hepat., [e-pub ahead of print].
28. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934; 26: 404–13.
29. García-Samaniego J, Romero M, Granados R et al. Factors associated with early virological response to peginterferon-α-2a/ribavirin in chronic hepatitis C. World J. Gastroenterol. 2013; 19: 1943–52.
30. Thomas DL, Thio CL, Martin MP et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798–801.
31. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41.